CompletedPhase 1NCT02043665
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
Studying Small cell carcinoma of the bladder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Viralytics
- Principal Investigator
- Hardev Pandha, MDRoyal Surrey County Hospital NHS Foundation Trust
- Intervention
- CVA21/pembrolizumab(biological)
- Enrollment
- 85 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2020
Study locations (18)
- John Wayne Cancer Institute, Santa Monica, California, United States
- University of Miami, Coral Gables, Florida, United States
- Advocate Health, Niles, Illinois, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Providence Portland Medical Center, Portland, Oregon, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- UT Southwestern, Dallas, Texas, United States
- Huntsman Cancer Institute, Salt Lake City, Utah, United States
- Tasman Oncology Research, Southport, Queensland, Australia
- Monash Health, Clayton, Victoria, Australia
- St Vincent's Hospital, Melbourne, Fitzroy, Victoria, Australia
- Barwon Health, Geelong, Victoria, Australia
- Epworth HealthCare, Richmond, Victoria, Australia
- St John of God Healthcare, Subiaco, Western Australia, Australia
- +3 more locations on ClinicalTrials.gov
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02043665 on ClinicalTrials.govOther trials for Small cell carcinoma of the bladder
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1NCT07218003A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4Rondo Therapeutics
- RECRUITINGPHASE2NCT06161532Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06228066Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT06257264A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsBeiGene
- RECRUITINGPHASE2NCT05312671Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNCT05621837Quantifying Systemic Immunosuppression to Personalize Cancer TherapyFondazione IRCCS Istituto Nazionale dei Tumori, Milano
- ACTIVE NOT RECRUITINGNCT05219734MRD Assay Evaluates Recurrence and Response Via a Tumor Informed AssessmentInvitae Corporation
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04644068Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesAstraZeneca